what compound is cagrilintide | C194H312N54O59S2 | CID 171397054 Cagrilintide 10mg | Research Peptide

[1] The more advanced regulatory activity belongs to the combination product CagriSema (cagrilintide plus semaglutide), which reached Phase 3 and for which a New Drug Application was reported to have been filed with the FDA in late 2025

Retatrutide = three axes in one molecule (GIP + GLP-1 + glucagon), both sides of energy balance

Apply these five checks to the popular claim retatrutide is far better than cagrilintide and it quickly reduces to: a 48-week top-dose monotherapy number for one, next to a 26-week monotherapy number for the other whose real strength is a combination with no head-to-head trial anywhere in the chain

But those are different trials with different durations and doses, and cagrilintides strongest data are as the CagriSema combination, so any ranking is a cross-trial inference rather than a proven result

Comparing the raw numbers as if they were a head-to-head duel manufactures a certainty the evidence does not support

The most defensible reading is to treat each compounds own within-trial data as its evidence and to treat any cross-compound ranking as a hypothesis, not a result